No more bulky files lying around, and no more having to spend 15 minutes looking for a file: everything we need is easily accessible in Merus. We have used other case management systems, but Merus is …

Merus has exclusively licensed Betta Pharmaceuticals Co. Ltd. to develop and potentially commercialize MCLA-129 in China, while Merus retains full rights ex-China.

Oct 1, 2025 · Genmab intends to acquire all the shares of Merus and its late-stage, first-in-class cancer drug petosemtamab for approximately $8 billion. Petosemtamab, with pembrolizumab, is in Phase III …

Dec 30, 2025 · Genmab A/S has completed its acquisition of Merus N.V. (NASDAQ:MRUS), according to a press release statement based on a recent SEC filing. The transaction was finalized Monday …

Dec 12, 2025 · The depositary for the Offer has advised Genmab and Purchaser that, as of the Expiration Time, a total of 71,463,077 of Merus’ issued and outstanding common shares, constituting …

Dec 16, 2025 · Get the latest Merus N.V. (MRUS) stock price with news, financials and other important investing information.

Merus appears to be a young humanoid. In his mortal form, he has greyish colored hair and purplish skin, while in his Angel form, he has white hair and blue skin. He also has a bowl haircut and a lean …

Find the latest Merus N.V. (MRUS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 21, 2025 · Merus is a nationally recognized, 100% employee-owned design-build development firm specializing in the construction, development, ownership, and management of a diverse real estate …

Nov 24, 2025 · MRUS | Complete Merus N.V. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.